FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...
GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of ...
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...
The US Food and Drug Administration (FDA) has accepted for review GSK’s Biologics License Application for depemokimab.
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
GSK plc (GSK) has announced on Monday that the FDA has accepted its Biologics License Application (BLA) for depemokimab for regulatory review in two indications.The proposed ...
Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback